What is claimed is:

1. A pharmaceutical composition comprising a hydrochloride salt of transnorsertraline or a hydrate thereof, mannitol, magnesium stearate, talc and sodium starch glycolate, wherein said mannitol contains less than 0.1% by weight of mannose.

2. The pharmaceutical composition of claim 1 which is in tablet or capsule form.

3. The pharmaceutical composition of claim 1, wherein the composition comprises at least 10% by weight of mannitol.

4. Use of a compound or composition of any one of claims 1 to 3 in the manufacture a medicament for treating, or preventing or managing a neurological disorder.

5. The use of claim 4, wherein the neurological disorder is selected from the group consisting of depression, cognitive deficits, fibromyalgia, pain, a sleep related disorder, chronic fatigue syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), restless leg syndrome, schizophrenia, anxiety, obsessive compulsive disorder, posttraumatic stress disorder, seasonal affective disorder (SAD), premenstrual dysphoria, post-menopausal vasomotor symptoms, a neurodegenerative disease, manic conditions, dysthymic disorder, cyclothymic disorder, obesity, and substance abuse or dependency.